This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| ICD-10 code | G63.0 |
|---|---|
| Special Copayment Reduction code | V170 |
| Synonyms / related terms | Infectious polyneuropathy, GBS (Guillain-Barré syndrome), leprous neuropathy, HIV neuropathy, Lyme neuroborreliosis |
| Classification | Severe intractable disease (Special Copayment Reduction registration criteria: 5 years) |
Polyneuropathy in infectious and parasitic diseases began to be recognized clinically from the late 19th century. In 1859, Landry described acute ascending paralysis, and afterward Guillain, Barré, and Strohl (1916) established modern Guillain-Barré syndrome (GBS), whose main antecedent causes are infections such as Campylobacter jejuni and CMV.
Leprosy (Hansen disease)-related neuropathy is direct invasion of peripheral nerves by Mycobacterium leprae and has long been recognized as the most common infectious neuropathy worldwide. Peripheral neuropathy associated with HIV infection has been studied extensively since the AIDS epidemic of the 1980s, and direct viral neural invasion is distinguished from antiviral drug toxic neuropathy.
ICD-10 G63.0 covers polyneuropathy in infectious and parasitic diseases classified elsewhere; the causative disease is classified under a separate code (B codes, etc.), and the neuropathy is coded as a secondary phenotype. In Korea it is classified as a severe intractable neurological disease eligible for Special Copayment Reduction (V170).
The infectious diseases causing polyneuropathy corresponding to G63.0 are broad, including bacteria, viruses, parasites, and fungi. The main classification by cause is as follows.
Bacterial causes: leprosy (M. leprae; direct peripheral nerve invasion), Lyme neuroborreliosis (Borrelia burgdorferi; involvement of cranial nerves and nerve roots), diphtheria (Corynebacterium diphtheriae; demyelinating), tuberculosis (M. tuberculosis; tuberculoma, complicated by meningitis), GBS after Campylobacter jejuni enteritis, and polyneuropathy after Salmonella.
Viral causes: HIV (primary AIDS neuropathy, antiretroviral-induced toxic neuropathy), CMV (cytomegalovirus polyradiculitis), GBS after EBV, varicella-zoster virus (VZV; postherpetic neuralgia, polyradiculitis), HTLV-1 (neuropathy accompanying tropical spastic paraparesis), and enterovirus-associated motor neuropathy.
Parasitic and other causes: Chagas disease (autonomic neuropathy), malaria (complicated by cerebral malaria), schistosomiasis, and filariasis-related nervous system involvement are rarely reported.
G63.0 is a neuropathy due to acquired infection and has no primary genetic cause. However, the individual's genetic background influences susceptibility to post-infectious neuropathy.
In GBS, it has been reported that the HLA-B*35 and HLA-DQ2 genotypes are associated with the occurrence of GBS after Campylobacter infection. The extent of nerve involvement in leprosy is influenced by the host's cell-mediated immune response (Th1/Th2 balance) and by polymorphisms in genes related to IL-12 and TNF-alpha.
In HIV-associated neuropathy, the toxicity of nucleoside reverse transcriptase inhibitors (NRTIs), which induces mitochondrial DNA depletion, manifests more severely in patients carrying mitochondrial DNA polymerase gamma (POLG) gene variants. An association between chronicity of Lyme neuropathy and HLA-DR4 has also been reported. These genetic elements can be used to predict clinical susceptibility but are not subjects of routine genetic testing.
The epidemiology of infectious polyneuropathy differs greatly according to the regional distribution of the causative infectious disease. Worldwide, leprosy-related peripheral neuropathy remains the most common infectious neuropathy, with India, Brazil, and Indonesia the main countries of occurrence. In Korea, new cases of leprosy have been extremely rare since 1977.
The frequency of HIV-associated neuropathy has decreased since the introduction of antiretroviral therapy (ART), but clinical neuropathy is observed in 30-50% of untreated HIV patients. The incidence of GBS (most often occurring after infection) is 1-2 per 100,000 per year, and it is most commonly preceded by Campylobacter infection (about 25-40%).
Lyme neuroborreliosis occurs in Europe and North America, and reports are rare in Korea. Herpes zoster-related neuropathy (including postherpetic neuralgia) is increasing in the aging population. In Korea, registration of patients for Special Copayment Reduction (V170) is determined by the type of underlying infectious disease and whether treatment is refractory.
The pathophysiology of infectious polyneuropathy is divided broadly into three types according to the causative microorganism: direct nerve invasion, toxin-mediated, and immune-mediated.
Direct nerve invasion: M. leprae directly invades Schwann cells and causes demyelination. CMV infects endoneurial vascular endothelial cells and causes polyradiculoneuropathy. VZV, after lying latent in the dorsal root ganglion, reactivates and causes ganglionitis and radiculitis.
Toxin-mediated: Diphtheria toxin inhibits protein synthesis in Schwann cells and causes demyelinating neuropathy. Botulinum toxin acts at the neuromuscular junction, but some toxin-producing bacterial infections can cause polyneuropathy.
Immune-mediated: GBS is an autoimmune demyelinating or axonal injury neuropathy triggered by molecular mimicry between the lipopolysaccharide (LPS) of Campylobacter jejuni and peripheral nerve gangliosides (GM1, GD1a, GQ1b). Anti-GM1, anti-GD1b, and anti-GQ1b antibodies are each associated with different clinical subtypes (AIDP, AMAN, AMSAN, MFS).
The clinical presentation of infectious polyneuropathy varies according to the type of underlying infection and the type of neuropathy (demyelinating, axonal, ganglionitis, autonomic neuropathy). Common symptoms are distal symmetric sensory loss and paresthesia (numbness, burning sensation), distal muscle weakness, and loss or reduction of deep tendon reflexes.
In GBS, ascending symmetric limb paralysis progresses rapidly within days to weeks after a preceding infection (mostly upper respiratory or gastrointestinal infection), and respiratory muscle paralysis may require mechanical ventilation. Cranial nerve involvement (facial palsy, dysphagia) and autonomic abnormalities (heart rate fluctuation, blood pressure instability, bladder dysfunction) accompany.
Leprous neuropathy is marked by loss of temperature and pain sensation, and loss of sensation at the site of skin lesions (depigmented macules, nodules) is characteristic. In HIV-infected neuropathy, foot pain, burning sensation, and allodynia are common. Lyme neuroborreliosis combines radicular pain, cranial nerve palsy (especially facial nerve), and meningitis.
On neurological examination, distal muscle weakness (decreased MRC grade), distal sensory loss (vibration, position, pain, temperature sense), and loss of deep tendon reflexes are the core findings. In GBS, ascending limb paralysis progresses rapidly, and reduced respiratory muscle strength (negative inspiratory force, NIF) predicts the need for mechanical ventilation.
Autonomic signs: orthostatic hypotension, alternating tachycardia/bradycardia, urinary retention, sweating abnormalities, and abnormal pupillary response suggest autonomic involvement. On leprosy examination, thickened peripheral nerves (great auricular nerve at the earlobe, ulnar nerve on the medial elbow, common peroneal nerve at the popliteal area) can be palpated.
When autonomic instability in GBS is severe (especially in the first 24-48 hours of admission), intensive care unit monitoring is needed. Examination of cranial nerve involvement (corneal reflex, facial sensation, palatal reflex, phonation, eye movements) is performed systematically. Distinguishing demyelinating versus axonal patterns with electromyography/nerve conduction studies is important for predicting prognosis and response to immunotherapy.
Nerve conduction studies (NCS) and electromyography (EMG) are essential for confirming and classifying polyneuropathy (demyelinating, axonal, mixed). In GBS, absent or delayed F waves, decreased motor nerve conduction velocity, decreased compound muscle action potential (CMAP), and abnormal sensory nerve conduction are observed.
A serum antiganglioside antibody panel (anti-GM1, anti-GQ1b, anti-GD1b, anti-CASPR2, etc.) is used for GBS subtype classification and diagnosis of Miller-Fisher syndrome. In cerebrospinal fluid (CSF) examination, albuminocytologic dissociation of GBS (increased protein, normal cell count) is characteristic.
Tests to identify the infectious agent: Campylobacter culture/antibody, CMV/EBV/VZV PCR and serology, HIV antibody/viral load, Lyme ELISA/Western blot, HTLV-1 antibody, and M. leprae skin biopsy/PCR are performed depending on the cause. Other imaging tests (spinal MRI) are used to exclude meningitis, nerve root inflammation, and spinal cord lesions.
The G63.0 diagnosis integrates three elements: clinical symptoms, electrophysiologic confirmation, and identification of the underlying infectious cause. GBS diagnostic criteria (Brighton Collaboration criteria or Asbury-Cornblath criteria) include ① bilateral limb weakness, ② loss or reduction of deep tendon reflexes, ③ symptom progression within 4 weeks, ④ CSF albuminocytologic dissociation, and ⑤ abnormal NCS.
Diagnosis of leprous neuropathy: confirmed by skin biopsy (slit-skin smear, identification of acid-fast bacilli in full-thickness skin biopsy), nerve biopsy (atypical Schwann cells, granulomatous infiltration), and cutaneous sensory mapping (thermal/pain mapping).
Lyme neuroborreliosis: ELISA followed by Western blot confirmation (two-tier serologic testing), calculation of the CSF Borrelia antibody index (AI), CSF PCR. HIV neuropathy: diagnosed by HIV viral load, CD4 count, antiretroviral drug history, and nerve conduction studies. For registration for Special Copayment Reduction (V170), submit a specialist's diagnosis certificate, NCS results, and test results confirming the causative infection.
Treatment consists of two pillars: treatment of the underlying infectious cause and treatment of the neuropathy itself.
Treatment of the cause: for leprosy, the WHO multidrug therapy (MDT; rifampin + dapsone +/- clofazimine) aims at eradication of the bacilli. For HIV-related neuropathy, optimizing ART for viral suppression is key, and NRTIs that cause toxic neuropathy (stavudine, didanosine) are replaced. For GBS, intravenous immunoglobulin (IVIG; 0.4 g/kg/day × 5 days) or plasma exchange (total 200-250 mL/kg, 4-6 sessions) is the standard treatment, and the efficacy of the two treatments is equivalent. For Lyme neuropathy, ceftriaxone or doxycycline is the drug of choice. CMV polyradiculitis is treated with ganciclovir or foscarnet.
Symptomatic treatment: tricyclic antidepressants (amitriptyline), duloxetine, gabapentin, and pregabalin are used for neuropathic pain. Mechanical ventilation in severe GBS, management of autonomic instability, prevention of pressure ulcers, prevention of deep vein thrombosis, and rehabilitation (physical therapy, occupational therapy) are the core of inpatient management.
Prognosis varies greatly depending on the type of causative infection, the neuropathy subtype, and the timing of treatment initiation. About 85% of GBS patients recover independent walking within 6 months, but about 5-10% have permanent neurological deficits, and mortality is about 3-5% in an intensive care setting. Poor prognostic factors are advanced age, preceding diarrhea, rapid progression, and marked reduction of CMAP amplitude (axonal injury).
Leprous neuropathy can recover neural function with early MDT treatment, but axonal damage that has already progressed is irreversible. Ulcers, burns, and trauma caused by sensory loss due to nerve damage within the area may recur, so preventive education is important.
HIV-associated neuropathy can have its symptom progression slowed by optimizing ART, but complete recovery is often difficult. Toxic neuropathy can be expected to partially recover within several months after replacing the antiretroviral drug. Lyme neuropathy mostly recovers after appropriate antibiotic treatment, but long-term neurological deficits may remain if treatment is delayed.
The key to preventing infectious polyneuropathy is prevention and early treatment of the underlying infection. Leprosy prevention: the BCG vaccine has a partial preventive effect against leprosy, and early diagnosis and MDT treatment block transmission. In endemic areas, early contact tracing and chemoprophylaxis are recommended.
GBS prevention: reducing Campylobacter infection through food safety management is important. The risk of GBS related to influenza vaccine is much lower than the risk of GBS from influenza infection itself, so vaccination is recommended. HIV prevention: safe sexual practices, no sharing of injection needles, and pre- and post-exposure prophylaxis (PrEP, PEP) prevent HIV infection itself.
Lyme disease prevention: in areas with high tick exposure, wearing protective clothing, using tick repellent, and thorough body checks after outings are recommended. Herpes zoster vaccine (recombinant, RZV; Shingrix) is effective in preventing herpes zoster and related neuropathy (postherpetic neuralgia) in people aged 50 and over.